A rare complication of imatinib mesylate therapy: drug-induced pneumonitis


Cite item

Full Text

Abstract

The use of imatinib mesylate (Glivec®) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease. The drug is generally tolerated well; the proportion of patients in whom imatinib treatment results in the development of toxic complications is small. Drug-induced interstitial pneumonitis associated with imatinib therapy is a rare complication that requires timely differential diagnosis, discontinuation of an inductor (imatinib), and altered further treatment policy.

References

  1. Практические рекомендации по лечению больных хроническим миелолейкозом: Пособие для врачей. M.; Тверь: OOO "Изд-во "Триада"; 2006.
  2. O'Brien S. G., Guilhot F. G., Goldmann G. V. et al. International randomized study interferon versus STI571(IRIS) 7-year follow up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 2008; 112: 76, abstr. 186.
  3. Deininger M. N. Chronic myeloid leukemia. Management of early stage disease. J. Hematology. Am. Soc. Hematol. 2005. Atlanta. 174-182.
  4. Guilhot F. G., Roy L., Millot F. Update of first-line in chronic phase chronic myeloid leukemia. Jn: Hematology. Education program of the 11 Congress of EHA, Amsterdam, the Netherlands, June 15-18, 2006: 93-97.
  5. Drucker B. J., Talpaz M., Resta D. et al. Efficacy and safety of specific ingibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001; 344: 1031-1037.
  6. Rajda J., Phatak P. D. Reversible drug-induced interstitial pneumonitis following imatinib mesilate therapy. Am. J. Hematol. 2005; 79: 79-82 (www.interscince.wilev.com).
  7. Common Terminology Criteria for Adverse Events (CTCAE) ver-sion3.0, DCTD, NCI, NIH, DHHS March 31, 2003 (http://ctep.cancer.gov), Publish date December 12, 2003.
  8. Фаучи Э., Браунвальд Ю., Иссельбахер К. и др. (ред.). М.: Внутренние болезни по Тинсли Р. Харрисону. М.: Практика Мак-гроу-Хилл (совм. изд.); 2002; т. 2: 1725, 1764- 1768.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies